PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOxaliplatin
Oxaliplatin
Oxaliplatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Oxaliplatin (discontinued: Eloxatin, Oxaliplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxaliplatin
Tradename
Company
Number
Date
Products
OXALIPLATINTevaN-022160 RX2009-08-07
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
oxaliplatinANDA2026-08-24
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XA: Platinum compounds, antineoplastic drugs
— L01XA03: Oxaliplatin
HCPCS
Code
Description
J9263
Injection, oxaliplatin, 0.5 mg
Clinical
Clinical Trials
3410 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——1845432042094933
Stomach neoplasmsD013274EFO_0003897C1680359117653550
Rectal neoplasmsD012004——6026487336413
Pancreatic neoplasmsD010190EFO_0003860C2511122548128357
NeoplasmsD009369—C8014215047720328
AdenocarcinomaD000230——4422656318316
Colonic neoplasmsD003110—C184911963428234
Neoplasm metastasisD009362EFO_0009708—4311831818200
Liver neoplasmsD008113EFO_1001513C22.02095481133192
Hepatocellular carcinomaD006528—C22.01310745230182
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal neoplasmsD004938—C15319911—13136
Large b-cell lymphoma diffuseD016403—C83.3184414—266
Peritoneal neoplasmsD010534——152310—852
RecurrenceD012008——8356—350
Non-small-cell lung carcinomaD002289——31231——49
Neoadjuvant therapyD020360——22210—1042
Gallbladder neoplasmsD005706EFO_0004606C2311276—240
Renal cell carcinomaD002292EFO_0000376—16192—134
Esophageal squamous cell carcinomaD000077277——10219——34
Ovarian neoplasmsD010051EFO_0003893C5619161—233
Show 73 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501317——837
Bile duct neoplasmsD001650——813——119
Head and neck neoplasmsD006258——313——218
Squamous cell carcinoma of head and neckD000077195——98———15
Appendiceal neoplasmsD001063EFO_0003880C18.174——314
Triple negative breast neoplasmsD064726——84——112
Ovarian epithelial carcinomaD000077216——58——112
Transitional cell carcinomaD002295——57———11
Endometrial neoplasmsD016889EFO_0004230—66———10
MelanomaD008545——103———10
Show 133 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma cutaneousD016410—C84.A3————3
MucositisD052016EFO_1001898—1———23
Pseudomyxoma peritoneiD011553EFO_0007456—1———23
Skin neoplasmsD012878EFO_0004198C442————2
Lymphomatoid granulomatosisD008230—C83.82————2
Pleural effusionD010996—J901———12
Pleural neoplasmsD010997——1———12
Sezary syndromeD012751—C84.12————2
Large-cell lymphoma anaplasticD017728—C84.62————2
Mycosis fungoidesD009182—C84.02————2
Show 36 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal and gastric varicesD004932EFO_0009545I85————44
HypertensionD006973EFO_0000537I10————33
PrognosisD011379——————22
HemorrhageD006470MP_0001914R58————22
Portal hypertensionD006975EFO_0000666K76.6————22
SarcopeniaD055948EFO_1000653M62.84————22
Body weightD001835EFO_0004338—————11
Plasma cell neoplasmsD054219——————11
Fatal outcomeD017809——————11
StentsD015607——————11
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOxaliplatin
INNoxaliplatin
Description
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
Classification
Small molecule
Drug classantineoplastics (platinum derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID61825-94-3
RxCUI—
ChEMBL IDCHEMBL414804
ChEBI ID—
PubChem CID11947679
DrugBankDB00526
UNII ID04ZR38536J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxaliplatin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
82,312 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use